Clinical trials: Inhibitory Control
- Condition Inhibitory Control
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Obesity
Safety Study of the Inhibition of Agouti-related Protein (AgRP) for the Management of Obesity and Weight Loss
Multiple pathways including peripheral and central hormones and neurotransmitters are involved in the regulation of food intake and body weight. One of the most studied pathways involves the melanocortin receptor.
- Trial name
- NCT00779519
- Testing
- TTP435
- Where
- 12 sites in United States, Canada
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- vTv Therapeutics
Influenza
A Double-Dose Safety Study of An Influenza Vaccine (Multimeric-001) Injected to Elderly Volunteers
This is a phase I/II, randomized, single-blind, placebo-controlled escalating double-dose study of the safety and priming potential of an intramuscular Influenza vaccine (Multimeric-001) injected to elderly volunteers.
- Trial name
- NCT01010737
- Testing
- Multimeric-001 250 mcg, Adjuvanted Multimeric-001 250mcg, Adjuvant: Montonide isa 51 VG
- Where
- Israel
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- BiondVax Pharmaceuticals ltd.
Reflux
Study to Investigate the Pharmacodynamic Effect of a Single Dose of AZD2516 in Healthy Male Subjects
The purpose of this study is to investigate the pharmacodynamic effect of AZD2516 in healthy male subjects.
- Trial name
- NCT01154634
- Testing
- AZD2516, 5 mg, AZD2516, 16 mg, AZD2516, 40 mg
- Where
- 2 sites in Belgium, Netherlands
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
Safety of AEB071 in Healthy Volunteers and to Compare the Ethnicity, Metabolic, and Safety Effects Between Caucasian and Japanese Healthy Subjects
This is a study to assess the safety effects after multiple doses of AEB071 in healthy volunteers and to compare the ethnicity, metabolic, and safety effects between Caucasian and Japanese healthy subjects receiving single and…
- Trial name
- NCT00416546
- Testing
- AEB071
- Where
- Canada
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Novartis
Inhibition of Plaque Formation (by Gingivitis-Index ≤1.5)
Study to Assess the Inhibition of Plaque Formation in Subjects With a Gingival Index ≤1.5
The objective of the study is to demonstrate the superiority of 0.1% octenidine mouthwash (Octenidin Mundspüllösung, OML) to placebo (PLAC) in the inhibition of plaque formation.
- Trial name
- NCT03378401
- Testing
- Octenidinedihydrochlorid
- Where
- 3 sites in Austria, Germany
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Schülke & Mayr GmbH
Influenza, Healthy
A Study to Assess the Safety and Immunogenicity of M-001 Influenza Vaccine as a Primer to TIV in Elderly Volunteers
"Multimeric-001" (M-001) has been recently developed, containing conserved, common linear influenza epitopes that activate both cellular and humoral arms of the immune system against a wide variety of influenza A and B strains.
- Trial name
- NCT01419925
- Testing
- Two Multimeric-001 administrations followed by TIV, One administration of Multimeric-001 followed by TIV, One administration of adjuvanted M-001 followed by TIV
- Where
- Israel
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- BiondVax Pharmaceuticals ltd.
Long QT Syndrome
Study of LQT-1213 on QTc-induced Prolongation in Healthy Adult Subjects (Part1) and on Congenital Long QT in Patients Diagnosed With Type 2 or 3 Long QT Syndrome (Part 2).
Part 1: This is a Phase 1b, randomized, double-blind, crossover, dose escalation, placebo-controlled study to evaluate the effect of oral LQT-1213 on dofetilide-induced QTc prolongation in healthy adult subjects.
- Trial name
- NCT05906732
- Testing
- LQT-1213, Dofetilide 250 μg Cap
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Thryv Therapeutics, Inc.
ALS (Amyotrophic Lateral Sclerosis)
This Study Evaluates the Safety, Target Engagement, and Preliminary Efficacy of Galunisertib (TGF-βR1/ALK5 Inhibitor)Combined With Nerandomilast (PDE4 Inhibitor) in GREM2-positive ALS, a Biomarker-defined Subgroup Hypothesized to Reflect Heightened TGF-β/SMAD-driven Astrocytic and Fibrotic Signaling
Amyotrophic lateral sclerosis (ALS) is a relentlessly progressive neurodegenerative disorder characterized by loss of upper and lower motor neurons, leading to muscle weakness, respiratory decline, and eventual mortality.
- Trial name
- NCT07321860
- Testing
- Galunisertib + Nerandomilast Combination
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Gipfel Life Sciences GmbH
Inhibition of Plaque Formation (by Gingivitis-Index ≤1.5)
Study to Assess the Inhibition of Plaque Formation in Subjects With a Gingival Index ≤1.5
The objective of the study is to demonstrate the superiority of 0.1% octenidine mouthwash (Octenidin Mundspüllösung, OML) to placebo (PLAC) in the inhibition of plaque formation.
- Trial name
- NCT03322124
- Testing
- Octenidinedihydrochlorid
- Where
- 3 sites in Germany
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Schülke & Mayr GmbH
Hypoactive Sexual Desire Disorder
Lybridos in Pre- and Postmenopausal Women With Hypoactive Sexual Desire Disorder Due to Maladaptive Activation of Sexual Inhibitory Systems
A double-blind, randomized, placebo-controlled, dose-finding study to investigate the safety and efficacy of Lybridos in the domestic setting in healthy female subjects with hypoactive sexual desire disorder and maladaptive…
- Trial name
- NCT01743235
- Testing
- Testosterone, Buspirone hydrochloride
- Where
- 12 sites in United States
- Volunteers
- 207 people, healthy volunteers welcome
- Sponsor
- Emotional Brain NY Inc.
Gastric pH Control
Magnesium Pantoprazole 20mg b.i.d. vs Magnesium Pantoprazole 40mg q.d. on Intragastric Acid Inhibition
The purpose of this study is to determine if magnesium pantoprazole 20 mg twice a day (b.i.d.), maintains gastric pH above 4 during a longer percentage of time than magnesium pantoprazole 40 mg once a day (qd).
- Trial name
- NCT01499693
- Testing
- Magnesium Pantoprazole 20 mg, Magnesium Pantoprazole 40 mg
- Where
- Mexico
- Volunteers
- healthy volunteers welcome
- Sponsor
- Takeda
Pain
A Microneurography Study of NaV1.8 Inhibition in Healthy Adults
The purpose of this study is to determine the effects of Nav1.8 inhibition on activity-dependent slowing (ADS) of C-nociceptor nerve fibers, evoked action potential (AP) conduction velocity of C-nociceptor nerve fibers using…
- Trial name
- NCT06420765
- Testing
- VX-150, VX-548, VX-993
- Where
- United Kingdom
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Vertex Pharmaceuticals Incorporated
Platelet Inhibition
A Study Assessing Inhibition of Serum Thromboxane B2 Levels With PN400 and Low Dose Aspirin
The primary hypothesis of this study is that concomitant multiple-dose administration of PN 400 does not interfere with the platelet inhibitory effects of enteric-coated low-dose aspirin (81 mg), as measured by serum thromboxane…
- Trial name
- NCT01094483
- Testing
- PN400, ASA
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Cachexia
Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic Study of GSK2881078 and Study to Evaluate the Effect of CYP3A4 Inhibition on PK of GSK2881078
GSK2881078 is a selective androgen receptor modulator (SARM) that is being evaluated for effects on muscle growth and strength in subjects with muscle wasting to improve their physical function.
- Trial name
- NCT02567773
- Testing
- GSK2881078, Itraconazole
- Where
- United States
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Volunteers
First in Man Study of ALX-0651, a Nanobody Inhibiting CXCR4
The purpose of this first-in-man Phase I study is to determine whether the CXCR4-inhibitor ALX-0651 is safe and effective after single or multiple intravenous administrations to healthy male volunteers.
- Trial name
- NCT01374503
- Testing
- ALX-0651
- Where
- Netherlands
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Ablynx, a Sanofi company
Pain
Omnitram Pharmacokinetic and Analgesic Study Following CY2D6 Inhibition With Paroxetine In Healthy Volunteers
This study evaluates the analgesic effect of Omnitram and tramadol during concurrent administration of paroxetine. Paroxetine administration is expected to diminish the analgesic effect of tramadol, but not Omnitram.
- Trial name
- NCT03312777
- Testing
- Omnitram, Tramadol
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Syntrix Biosystems, Inc.
Hypertension
Hemodynamic Effects of Aliskiren Compared to Captopril on the Kidney in Healthy Volunteers on a Low- and High- Sodium Diet
This study will measure the effects of different doses of aliskiren on kidney blood flow and function in healthy adults and determine how salt intake affects the response to aliskiren.
- Trial name
- NCT00518765
- Testing
- Aliskiren
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Novartis
Thrombin Inhibition
Oral AZD8165 After Single Oral Ascending Doses in Healthy Male Subjects
The purpose of this study is to evaluate the safety and tolerability of AZD8165 and the pharmacokinetics of the metabolite AZ12971554 and plasma levels of the prodrug AZD8165 after escalating single oral low doses.
- Trial name
- NCT01150812
- Testing
- AZD8165
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Parkinson's Disease
Study to Investigate the Tolerability, Steady-state Pharmacokinetics and Erythrocyte COMT Inhibition of BIA 3-202
The purpose of this study is to investigate the tolerability and safety of three multiple dose regimens of nebicapone (BIA 3-202 100 mg, 200 mg, and 300 mg 6 times daily) in healthy volunteers.
- Trial name
- NCT02772627
- Testing
- Nebicapone
- Where
- Portugal
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Primary Hyperlipidemia and Mixed Dyslipidemia
Effects on Lipoprotein Metabolism From PCSK9 Inhibition Utilizing a Monoclonal Antibody
This is a randomized, double-blind, placebo-controlled trial to evaluate the effect of evolocumab, atorvastatin, and combination therapy on lipoprotein kinetics.
- Trial name
- FLOREY (NCT02189837)
- Testing
- Evolocumab, Atorvastatin
- Where
- 2 sites in Australia
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Amgen